Advancing precision drug through innovative chemistry and advanced molecular technologies.
Integrated CDMO services spanning discovery, process development, custom synthesis and commercial manufacturing.
Delivering reliable CDMO solutions for innovative therapeutics worldwide.
CHEMOS致力于打造以产品为牵引、合成技术驱动的CDMO品牌，为全球制药及生物技术公司提供端到端的CDMO技术服务。我们聚焦于药物递送系统（LNP、GalNAc）、生物偶联化学（ADC Linker）、放射性药物化学（DOTA、NOTA）、靶向蛋白降解（PROTAC、分子胶）及功能性分子砌块等高壁垒领域，依托先进的合成技术与分析平台，为客户提供从Discovery、Process Development、Custom Synthesis、Manufacturing到Analytical Development的全生命周期解决方案。我们致力于赋能创新药物的高效、低碳、规模化开发，加速从研发到商业化的转化进程。
了解我们最新发展与行业洞察
This article shares insights from multi-kg GMP campaigns for SM-102, an ionizable lipid used in Moderna’s mRNA-LNP platform. Batch scale-up often suffers from purity drops below 98%, broadened impurity profiles, and residual solvent exceedances due to poor heat/mass transfer, hot spots, and inconsistent pH/temperature control. The solution is a telescoped continuous flow process with micro/meso-fluidic reactors, in-line PAT (HPLC/FTIR), and continuous work-up/crystallization. Results show consistent impurity fingerprints, 30–40% higher yield, 99.5% purity, and <500 ppm residual solvents, establishing continuous flow as the only robust, ICH-compliant route for commercial SM-102 supply.
更多4-Chlorophenylhydrazine hydrochloride is a key intermediate for heterocyclic synthesis in pharmaceuticals and agrochemicals. Traditional processes face unstable diazonium salts, reducing agent caking, poor crystallization, low yields, high waste, and toxicity risks. The optimized CDMO process achieves high yield and purity through precise temperature/pH control, liquid reducing agent, and optimized crystallization, while integrating low‑temperature control, inert atmosphere, tail‑gas recycling, GMP production, and multi‑ton supply. Outsourcing reduces development time and compliance burdens. The process follows green chemistry principles and suits kinase inhibitors, antifungals, dyes, and more.
更多
Trifluoromethanesulfonic anhydride (Tf2O) is a highly efficient electrophilic activator in modern pharmaceutical synthesis, enabling precise introduction of fluorine atoms or trifluoromethyl groups into molecular scaffolds. This enhances metabolic stability, lipophilicity, and biological activity—key parameters in drug discovery. Its mechanism involves converting alcohols into reactive triflates, facilitating nucleophilic substitutions and cross-couplings. As a professional CDMO, we offer custom synthesis of Tf2O at ≥99% purity, scalable from gram to kilogram and beyond, with stringent quality control and fast delivery. Our services help pharmaceutical companies streamline fluorination steps, shorten synthetic routes, reduce costs, and accelerate the transition from lab to commercialization for novel fluorinated APIs.
无论您处于药物研发的哪个阶段——从早期发现到商业化生产，CHEMOS始终以领先的合成技术与CDMO服务平台，为您提供高效、可靠的一站式解决方案。
